Newsroom | 1319 results

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and vol...

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitimate and lawful actions of the Board. Dear Shareholders, We are writing to set the record straight in response to the Vivo gr...

MEXICO CITY & MIAMI & SÃO PAULO--(BUSINESS WIRE)--The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute acknowledge the conclusion of three years of negotiations on the global pandemic agreement text by congratulating the negotiators—particularly representatives of the Equity and Africa Groups—and recognizing the contributions of key stakeholders, including civil society, who championed equitable access to public health goods. “Even before the COVID-19 pandemic, we beg...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--The life sciences innovation ecosystem continued to evolve and expand in 2024 as the industry continued to adapt to a complex and dynamic range of geopolitical, technological and social uncertainties. The year saw progress in funding, trial starts, program productivity and cycle times, according to the new report, Global Trends in R&D 2025: Progress in Recapturing Innovation in Biopharma Innovation, released by the IQVIA Institute for Human Dat...

LONDON--(BUSINESS WIRE)--This year, International SOS marks its 40th anniversary, reflecting on 4 decades of safeguarding the health, security & wellbeing of clients worldwide...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one...

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing treatments and diagnostic tools for global public health and zoonosis concerns, will present new data from universal influenza pipeline candidates during two poster sessions at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025. Longhorn will also be available at booth C108 in Hall B to discuss its differentiated approach to the...

GOLDEN, Colo.--(BUSINESS WIRE)--Published analysis showed the GEMCOVAC-OM COVID-19 booster administered exclusively with Tropis ID induced a broad and long-lasting immune response....

SYDNEY--(BUSINESS WIRE)--Novotech Report Reveals Global Surge in Infectious Disease Trials as Industry Nears 2,000 Studies Since 2020...